Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

EXCERPT: 

February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant.

Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an expert in the study of mammary stem cell and breast cancer for the purposes of regenerative and cancer medicine. Prof. Zeng holds a postdoctoral degree in Developmental Biology from Stanford University. She has authored and co-authored various research papers on mammary development, multipotent mammary stem cells and breast cancer.

Please click below to read full announcement.

Click to download PDF.